AMD

A study reveals significant treatment burdens for patients with AMD and DME, highlighting the need for improved education and support to enhance outcomes.

Catch up on recent advancements in retina care, including new therapies for age-related macular degeneration and macular telangiectasia, enhancing patient outcomes.

The role of anesthetics in streamlining efficiency and elevating patient care.

Patients weigh in on the value of provider communication.

The DAVIO-2 study reveals EYP-1901's potential as a 6-month treatment for neovascular AMD, matching aflibercept's vision outcomes with fewer doses.

EYLUXV, a new biosimilar for treating serious eye conditions, gains positive EMA recommendation, promising improved patient access and outcomes.

Australian researchers highlighted the overlooked ocular risks surfers and divers face from UV and blue light exposure.

Vonaprument has received fast track designation from the US Food and Drug Administration.

Kiora Pharmaceuticals secures a patent for KIO-104, enhancing treatment options for ocular diseases and extending market exclusivity until 2043.

A new study links urinary metabolites from organophosphorus pesticides to increased age-related macular degeneration risk.

A hope for reducing treatment burden for wet age-related macular degeneration with a sustained-release vorolanib intravitreal insert

LumiThera’s PBM is the only device that has demonstrated meaningful vision improvement compared to baseline for people living with early to intermediate dry AMD.

Research from the iMIND lab at Duke University.

Recapping a recent conversation led by Dilsher S. Dhoot, MD.

Modern Retina’s recent Case-Based Roundtable focused on next-generation treatments for retinal disease that provide advanced care for neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME).

A new study from China revealed a genetic link between coffee consumption and age-related macular degeneration (AMD).

The gift will be used to treat and potentially cure eye diseases like macular degeneration and glaucoma, increase focus on basic science, and harness artificial intelligence to revolutionize vision care.

Brazilian regulatory authority ANVISA grants marketing authorization for Ranivisio.

The new surgical technique incorporates a new surgical clamp that maintains eye pressure during the insertion of two tissue patches in immediate succession while minimizing damage to the surrounding tissue.

Join global experts at the 2025 International SPECTRALIS Symposium in Heidelberg, exploring innovations in ophthalmology and space-related ocular health.

Lineage Cell Therapeutics will be presenting data on the safety and tolerability of RG6501 (OpRegen) for the treatment of geographic atrophy, secondary to age-related macular degeneration during the upcoming Clinical Trials at the Summit 2025 meeting.

Ashvattha Therapeutics announced positive interim phase 2 results for migaldendranib for the treatment of AMD and DME.